IQur Limited TSB Q8 Meeting 2 nd September 2009. Agenda MW: project update & meeting schedule AET: Leeds purification MW: in vivo data LB: new constructs/EM.

Slides:



Advertisements
Similar presentations
Serological tests (Antigen antibody interactions)
Advertisements

Research Techniques Made Simple: Enzyme Immunoassay and ELISA
Antibodies Analytical Techniques Utilizing Antibodies: flow cytometry
Building a Panel Select markers Select conjugates Method to build panel performance criteria.
Langzhou Song VaxInnate Corporation September 26, 2014 A Rationally Designed Form of The TLR5 Agonist, Flagellin, Supports Superior Immunogenicity of Influenza.
Biology Mathematics Engineering Optics Physics Robotics Informatics.
Introduction Determination of Chickens as a Useful Model for Antibody Production to Green Fluorescent Protein and a Tomato Proteinase Inhibitor II Peptide.
Research Techniques Made Simple: The Use of Luminex Assays To Measure Cytokines Saami Khalifian, B.A., Giorgio Raimondi, Ph.D., & Gerald Brandacher, M.D.
Antigens & Antibodies: reactions, detection, and applications.
Protein arrays LEAPS technology An array of 110 different antibodies incubated with various levels of the fluorescently labelled cognate antigens in a.
(Enzyme Linked Immunosorbent Assay)
Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71.
Antigen-Antibody Interactions : principles and Applications 미생물학교실 권 형 주.
ELISA (aka Enzyme-Linked Immunosorbent Assay) Professor C. Roth 125:315: BME Measurements and Analysis Laboratory Spring 2003.
Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.
TSB Meeting 4 Hepatacore iQur Leeds Progress. Overview Introduction CoHo7e,HA1s VLP purification Cloning Yeast cell lysis Future work.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Construction of Plasmids & Analysis of Yeast Lysates Update.
Basic Principles, Instrumentation, and Practices
TSB Q7 Meeting 02-Jun-2009 Hepatacore iQur Leeds Progress.
TSB Q6 Meeting 03-Mar-2009 Hepatacore iQur Leeds Progress.
The Enzyme Linked Immunosorbent Assay (ELISA).. Capture ELISAs Antigen Capture: In this, more specific approach, a capturing Ab is adsorbed onto the solid.
Western blotting. Antibodies in the Immune System Structure: 2 heavy chains + 2 light chains Disulfide bonds 2 antigen binding sites Isotypes: IgG, IgM,
Acid/Base Titration Buffers. Buffers A mixture composed of a weak acid and its conjugate base (acidic buffer) OR weak base and its conjugate acid (basic.
Construction of Plasmids & Purification of Core-Haemagglutinin VLPs.
CENTER FOR BIOLOGICAL SEQUENCE ANALYSIS BiC BioCentrum-DTU Technical University of Denmark Cleavage sites and binding affinities.
Heterologous Protein Expression in Yeast CoHo7e - Green, Core and HA Malcolm Stratford & Hazel Steels MOLOGIC.
TSB Q5 Meeting 16-Dec-2008 Hepatacore iQur Leeds Progress.
Genomic Screening Princess Kara Parker-Smith Marlyn Gonzalez and Dr. Peter Lipke Hunter College, CUNY Harlem Children Society.
FLUTCORE 6M project meeting Pampaloma April, 2016 Olotu Ogonah, Ben Blaha, Tarit Mukhopadhyay.
Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.
VLPs Products in Creative Biostructure. VLP Lipoparticles have many advantages in isolating membrane proteins: firstly, they are homogeneous and physically.
Multiplex analysis of cytokines Russell Garland KWS BioTest
KJ Hansen, JK Simons, TA Peterson
Development of Med28 Specific Monoclonal Antibodies
KM71H pHe7 LAHH3,K1 3P g VLP prep II Bradford assay
Cell Physiol Biochem 2016;38: DOI: /
Flutcore meeting 11/4/2016 by Alex Ramirez PhD.
Virus-like particle service Creative Biostructure has developed MemPro™ Virus-Like Particles (VLPs) Technology based on our magic Membrane Protein Production.
Vlp construction The formation of virus-like particles (VLPs) is a result of self- assembly of one or several types of viral structural proteins, such.
Vlp construction The formation of virus-like particles (VLPs) is a result of self-assembly of one or several types of viral structural proteins, such as.
Supplementary Figure 2 Secondary transplanted brain tumors from PASC1 express human GH. Immuno-fluorescence staining of brain sections from mice implanted.
Volume 117, Issue 6, Pages (December 1999)
Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)- based microparticles for intranasal vaccine delivery: Effect of surface modification.
Volume 17, Issue 8, Pages (August 2009)
Volume 16, Issue 2, Pages (February 2002)
Volume 130, Issue 2, Pages (February 2006)
by Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz
Volume 9, Issue 5, Pages (November 1998)
Protein microarrays: prospects and problems
Volume 18, Issue 5, Pages (May 2003)
Loss of vimentin in B cells impairs antibody response in vivo.
Volume 68, Issue 3, Pages (September 2005)
Volume 20, Issue 10, Pages (September 2017)
by Kalpana Parvathaneni, and David W. Scott
Refer to word document for this table
Volume 20, Issue 2, Pages (February 2013)
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5% to 2% (vol/vol) oil, as measured.
(Left) Selected IgM immunoblot reactivities.
Kevin M. Marks, Michael Rosinov, Garry P. Nolan  Chemistry & Biology 
Volume 8, Issue 22, Pages (November 1998)
Volume 23, Issue 8, Pages (August 2016)
Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley  Molecular Therapy 
RUBYTM – A novel recombinant universal bispecific antibody format for generation of bsAb with outstanding stability, manufacturability and shorter development.
Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength  Jackson G. Egen, James P. Allison  Immunity 
Volume 17, Issue 10, Pages (October 2009)
Full-length TAPL interacts specifically with LAMP-1 and LAMP-2.
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02% to 2% (vol/vol) oil, as measured.
Volume 23, Issue 2, Pages (August 2005)
NSG2 interacts with AMPAR subunits GluA1 and GluA2.
Presentation transcript:

iQur Limited TSB Q8 Meeting 2 nd September 2009

Agenda MW: project update & meeting schedule AET: Leeds purification MW: in vivo data LB: new constructs/EM MS: yeast expression LB: Arecor EM BD: stability studies

Dates for meetings Final meeting: Week beginning 30 th November 2009 UCL

Outstanding work (Q7) Arecor to develop stability buffer –In progress iQur to carry our pre and post in vivo study on this material (is there enough?) –Awaiting material Mologic to express and purify yeast derived material –In progress iQur to carry out in vivo study using this material –Awaiting material

Q8 TSB Meeting In vivo update

UCL14 Dual insert construct of sAg and GFP Formulated +/- adjuvant (alum) Engerix control at molar equivalent level to sAg insert Three vaccinations at weekly intervals Sampling at days +7, 21 and 28

UCL14 Core ELISA (d28) Core response maintained and strong No IgM at day 28 but was detected at day 7

UCL14 eGFP ELISA (d28) GFP response best when adjuvant present Dual and single Inserts have a very similar profile

UCL14 Surface ELISA (d28) No detectable surface antigen response Control working well Neither IgM or IgG

UCL15 Repeat of dual insert construct of sAg and GFP (sAg and GFP alone controls) Formulated in alum Engerix control at molar equivalent level to sAg insert 1,2 or 3 vaccinations at weekly intervals Sampling at days +7, +14 and +21

UCL 15 Core ELISA (d 7)

UCL 15 GFP ELISA (d 7)

UCL 15 sAg ELISA (d 7)

UCL15: ELISA Core response titrates for 1-3 doses GFP response titrates for 1-3 doses Plant derived GFP-VLP is positive Single sAg insert is weakly positive (day 7) but dual insert is not.

Flow cytometric analysis of VLPs Provides a rapid analysis of VLP structure Assay is simple enough to be used in batch process/release Provides data relating to the interaction of inserted epitopes Fully quantitative

Assay design GFP antigen detected in FL1 channel or use FITC conjugated antibody to insert 2 VLP immobilised onto protein G beads by anti-core PerCP conjugated antibody to insert 1 (or SA-PerCP)

Steric hindrance sAg single insert Antigen detected in upper quadrants sAg/GFP dual insert sAg is no longer detectable but beads do fluorescence green proving VLP has been captured Single sAg insertIsotype control Dual sAg GFP

Eden Final reports Draft Upstream Draft Downstream